| Scott Daniel Williams, CRNP | |
|
1022 1st St N Ste 500, Alabaster, AL 35007-8740 | |
| (205) 663-5775 | |
| (205) 664-2112 |
| Full Name | Scott Daniel Williams |
|---|---|
| Gender | Male |
| Speciality | Nurse Practitioner |
| Experience | 19 Years |
| Location | 1022 1st St N Ste 500, Alabaster, Alabama |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1972882025 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LA2100X | Nurse Practitioner - Acute Care | 1-104941 (Alabama) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Shelby Baptist Medical Center | Alabaster, AL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Hospital Physician Services - Southeast Professional Corporation | 5597774554 | 640 |
News Archive
University Hospitals Birmingham NHS Foundation Trust and AI specialist Skin Analytics are to pilot a new skin cancer community assessment service to safely reduce delays in skin cancer detection and treatment during the Coronavirus pandemic.
IBM's announcement of the first biodegradable nanoparticles that can seek out and destroy drug-resistant bacteria caps off a century of healthcare and life sciences innovation from IBM.
Rhinosinusitis (infection and inflammation in the sinus passages surrounding the nose) appears to be a primary factor in about one-fifth of toxic shock syndrome cases in children, according to a report in the June issue of Archives of Otolaryngology-Head & Neck Surgery.
Alkermes plc today announced the initiation of the second phase 2 study of ALKS 3831, a novel, oral, broad-spectrum antipsychotic medicine in development for schizophrenia.
› Verified 6 days ago
| Entity Name | Heart South Cardiovascular Group, P.c. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1588641005 PECOS PAC ID: 3476455668 Enrollment ID: O20040127000578 |
News Archive
University Hospitals Birmingham NHS Foundation Trust and AI specialist Skin Analytics are to pilot a new skin cancer community assessment service to safely reduce delays in skin cancer detection and treatment during the Coronavirus pandemic.
IBM's announcement of the first biodegradable nanoparticles that can seek out and destroy drug-resistant bacteria caps off a century of healthcare and life sciences innovation from IBM.
Rhinosinusitis (infection and inflammation in the sinus passages surrounding the nose) appears to be a primary factor in about one-fifth of toxic shock syndrome cases in children, according to a report in the June issue of Archives of Otolaryngology-Head & Neck Surgery.
Alkermes plc today announced the initiation of the second phase 2 study of ALKS 3831, a novel, oral, broad-spectrum antipsychotic medicine in development for schizophrenia.
› Verified 6 days ago
| Entity Name | Hospital Physician Services - Southeast Professional Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1760410385 PECOS PAC ID: 5597774554 Enrollment ID: O20140219000913 |
News Archive
University Hospitals Birmingham NHS Foundation Trust and AI specialist Skin Analytics are to pilot a new skin cancer community assessment service to safely reduce delays in skin cancer detection and treatment during the Coronavirus pandemic.
IBM's announcement of the first biodegradable nanoparticles that can seek out and destroy drug-resistant bacteria caps off a century of healthcare and life sciences innovation from IBM.
Rhinosinusitis (infection and inflammation in the sinus passages surrounding the nose) appears to be a primary factor in about one-fifth of toxic shock syndrome cases in children, according to a report in the June issue of Archives of Otolaryngology-Head & Neck Surgery.
Alkermes plc today announced the initiation of the second phase 2 study of ALKS 3831, a novel, oral, broad-spectrum antipsychotic medicine in development for schizophrenia.
› Verified 6 days ago
| Entity Name | Baptist Health Centers Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1265496236 PECOS PAC ID: 3476457011 Enrollment ID: O20180124001442 |
News Archive
University Hospitals Birmingham NHS Foundation Trust and AI specialist Skin Analytics are to pilot a new skin cancer community assessment service to safely reduce delays in skin cancer detection and treatment during the Coronavirus pandemic.
IBM's announcement of the first biodegradable nanoparticles that can seek out and destroy drug-resistant bacteria caps off a century of healthcare and life sciences innovation from IBM.
Rhinosinusitis (infection and inflammation in the sinus passages surrounding the nose) appears to be a primary factor in about one-fifth of toxic shock syndrome cases in children, according to a report in the June issue of Archives of Otolaryngology-Head & Neck Surgery.
Alkermes plc today announced the initiation of the second phase 2 study of ALKS 3831, a novel, oral, broad-spectrum antipsychotic medicine in development for schizophrenia.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Scott Daniel Williams, CRNP 1022 1st St N Ste 500, Alabaster, AL 35007-8740 Ph: (205) 663-5775 | Scott Daniel Williams, CRNP 1022 1st St N Ste 500, Alabaster, AL 35007-8740 Ph: (205) 663-5775 |
News Archive
University Hospitals Birmingham NHS Foundation Trust and AI specialist Skin Analytics are to pilot a new skin cancer community assessment service to safely reduce delays in skin cancer detection and treatment during the Coronavirus pandemic.
IBM's announcement of the first biodegradable nanoparticles that can seek out and destroy drug-resistant bacteria caps off a century of healthcare and life sciences innovation from IBM.
Rhinosinusitis (infection and inflammation in the sinus passages surrounding the nose) appears to be a primary factor in about one-fifth of toxic shock syndrome cases in children, according to a report in the June issue of Archives of Otolaryngology-Head & Neck Surgery.
Alkermes plc today announced the initiation of the second phase 2 study of ALKS 3831, a novel, oral, broad-spectrum antipsychotic medicine in development for schizophrenia.
› Verified 6 days ago
Stephanie Lynn Woods, Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 1000 1st St N, Alabaster, AL 35007 Phone: 205-620-7059 | |
Jenifer Justice, CRNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 145 Sundance, Alabaster, AL 35007 Phone: 662-640-8804 | |
Mrs. Amanda T Cabaniss, RN, CRNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 1024 1st St N, Central Alabama Oncology, Llc, Alabaster, AL 35007 Phone: 205-664-4051 Fax: 205-664-4054 | |
Brody Weldon, CRNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1000 1st St N, Alabaster, AL 35007 Phone: 205-620-7004 | |
Mr. Ricardo Paitz, ACNPC-AG Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1000 1st St N, Alabaster, AL 35007 Phone: 205-620-8100 | |
Jennifer Gafnea, CRNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 300 1st St N Ste C, Alabaster, AL 35007 Phone: 205-381-2381 | |
William Alexander Woodard, Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 300 1st Street North Ste. C, Alabaster, AL 35007 Phone: 205-663-5990 |